Pemetrexed: From preclinic to clinic;Pemetrexed: De la préclinique à la clinique

Bulletin du Cancer

Volumn 94, Issue SPEC. ISS., 2007, Pages

  Lansiaux, Amélie ^a   Lokiec, François ^b  

^a CENTRE OSCAR LAMBRET   (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

Antifolate; Mesothelioma; Pemetrexed

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLIC ACID ANTAGONIST; INTERFERON; METHOTREXATE; PEMETREXED;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CELL SYNCHRONIZATION; CELL TRANSPORT; CHEMICAL STRUCTURE; COLON CANCER; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MONOTHERAPY; REVIEW; SOLID TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EVALUATION, PRECLINICAL; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 34547801288     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0358     Document Type: Review

References (42)

1. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006 ; 24 : 37-77.
2. Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, et al., Pemetrexed Expanded Access Program Investigators. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma : Outcomes of an expanded access program. Lung Cancer 2007 ; 55 : 187-94.
3. Taylor EC, Kuhnt D, Shin C, Rinzek SM, Grindey GB, Barreto J, et al. Dideazatetrahydrofolate analogue lacking a chiral center at C-6, N [4- [2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo [2,3-d]pyrimidin-5-yl) ethyl] benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992 ; 35 : 4450-4.
4. Lokiec F. Pemetrexed : new multitargeted antimetabolite. Rev Pneumol Clin 2005 ; 61 : 4S5-4S7.
5. Rollins KD, Lindley C. Pemetrexed : a multitargeted antifolate. Clin Ther 2005 ; 27 : 1343-82.
6. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of Pemetrexed. Semin Oncol 2002 ; 29 : 3-17.
7. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiples folate enzyme inhibition : mechanism of a novel pytrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998 ; 38 : 135-52.
8. Calvert AH, Walling JM. Clinical studies with MTA. Br J Cancer 1998 ; 78 : 35-40.
9. Lansiaux A, Degardin M, Bailly C. LY231514. A multitargeted antifolate (MTA). Bull Cancer 1999 ; 86 : 727-31.
10. Zhao R, et al. Alimta® : a new generation antifolate. Oncologist 2004 ; 9 : 242-4.
11. Theti DS, Jackman AL. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 2004 ; 10 : 1080-9.
12. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo [2,3-d ]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997 ; 57 : 1116-23.
13. Faessel HM, Slocum HK, Jackson RC, Boritzki TJ, Rustum YM, Nair MG, et al. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes : their critical role in polyglutamylation. Cancer Res 1998 ; 58 : 3036-50.
14. Habeck LL, Shih C, Gossett LS, Leitner TA, Schultz RM, Andis SL, et al. Substrate specificity of mammalian folylpolysynthetase for 5,10-dideazatetrahydrofolare analogs. Mol Pharmacol 1995 ; 48 : 326-33.
15. Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995 ; 6 : 871-81.
16. Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C, et al. Preclinical cellular pharmacology of LY231514 (MTA) : a comparison with methotrexate, LY309887 and reltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998 ; 78 : 27-34.
17. Tonkinson JL, Marder P, Andis SL, Schulrz RM, Gossett LS, Shih Cn Mendelsohn LG. Cell cycle effects of antifolate antimetabolites : implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997 ; 39 : 521-31.
18. Eismann U, Oberschmidt O, Ehnert M, Fleeth J, Ludtke FE, Struck S, et al. Pemetrexed : mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors. Int J Clin Pharmacol Ther 2005 ; 43 : 567-9.
19. Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 1998 ; 18 : 3235-40.
20. Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna C, et al. Acrivity of the multitargeted Antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 1999 ; 44 : 105-10.
21. Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999 ; 19 : 437-43.
22. Chattopadhyay S, Zhao R, Krupenko SA, Krupenko N, Goldman ID. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006 ; 5 : 438-49.
23. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006 ; 9 : 227-46.
24. Hooijberg JH, de Vries NA, Kaspers GJ, Pieters R, Jansen G, Peters GJ. Multidrug resistance proteins and folate supplementation : therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 2006 ; 58 : 1-12.
25. Wang Y, Zhao R, Goldman ID. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol 2003 ; 65 : 1163-70.
26. Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol 1999 ; 44 : 427-32.
27. Takimoto CH, Mita AC. Design, conduct, and interpretation of organ impairment studies in oncology patients. J. Clin Oncol 2006 ; 24 : 3509-10.
28. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006 ; 24 : 552-62.
29. Rahman A, White RM. Cytotoxic anticancer agents and renal impairment study : the challenge remains. J Clin Oncol 2006 ; 24 : 533-6.
30. Latz JE, et al. Population pharmacokinetic analysis often phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006 ; 57 : 401-11.
31. Thodtmann R, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999 ; 17 : 3009-16.
32. Newell DR. Clinical pharmacokinetics of antitumor antifolates. Semin Oncol 1999 ; 26 : 74-81.
33. Latz JE, et al. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006 ; 57 : 412-26.
34. Latz JE, et al. Clinical application of a semi mechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006 ; 57 : 427-35.
35. Ouellet D, et al. Population pharmacokinetics of Pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemother Pharmacol 2000 ; 46 : 227-34.
36. Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006 ; 24 : 4840-7.
37. Von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen P, Gough J, et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 2006 ; 17 : 1533-8.
38. Dittrich C. Use of pemetrexed in breast cancer. Semin Oncol 2006 ; 33(3 Suppl 9) : S24-S28.
39. Hochster H, Kettner E, Kroning H, Becker K, Lordick F, Ramanathan RK, et al. Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005 ; 5 : 257-62.
40. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid : markers to predict and avoid toxicity from Pemetrexed therapy. Mol Cancer Ther 2002 ; 1 : 545-52.
41. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of Pemetrexed in combination with cisplatin verus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 ; 21 : 2636-44.
42. Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 2005 ; 16 : 345-51.